MedTrace Logo

Study of 3 Doses of ARD-0403 in Testosterone Deficient Men

NCT00597051 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2008-01-17

No results posted yet for this study

Summary

The purpose of this study is to determine which dose, if any, results in testosterone levels within the normal range for men.

Conditions

  • Hypogonadism

Interventions

DRUG

ARD-0403

Sponsors & Collaborators

  • Ardana Bioscience Ltd

    lead INDUSTRY

Principal Investigators

  • Tatiana Mokhort, MD · Republican Endocrinology Center Hospital, Minsk, Republic of Belarus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2006-02-28
Completion
2006-02-28

Countries

  • Belarus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00597051 on ClinicalTrials.gov